Catalyst Pharmaceuticals, Inc.
CPRX
$19.95
-$0.67-3.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.73% | 143.77% | 60.53% | 242.65% | 8.03% |
| Total Depreciation and Amortization | 0.26% | 0.32% | 3.45% | 10.31% | 10.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.00% | -88.60% | -74.15% | -109.77% | 4,141.94% |
| Change in Net Operating Assets | -89.06% | 18.46% | -41.90% | 832.98% | 155.06% |
| Cash from Operations | 11.17% | 88.08% | 27.37% | 61.48% | 108.54% |
| Capital Expenditure | -160.00% | -- | 99.76% | -304.69% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -160.00% | -- | 99.77% | 99.72% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.81% | -96.64% | 763.49% | 1,776.42% | 229.17% |
| Repurchase of Common Stock | -- | -214.71% | -2.43% | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.03% | 14.50% | -20.11% | 3.74% | -12.20% |
| Cash from Financing | -24.63% | -97.83% | 766.62% | 41.01% | 640.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.51% | -63.48% | 351.38% | 215.26% | 113.76% |